Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　― Results From EMPA-REG OUTCOME<sup>®</sup> ―-Reference-Cited by-同舟云学术

Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　― Results From EMPA-REG OUTCOME^® ―

Published:2017 Issue:2 Volume:81 Page:227-234
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kaku Kohei¹,Lee Jisoo²,Mattheus Michaela²,Kaspers Stefan²,George Jyothis³,Woerle Hans-Juergen²,

Affiliation:

1. Department of General Internal Medicine, Kawasaki Medical School

2. Boehringer Ingelheim Pharma GmbH & Co. KG

3. Boehringer Ingelheim Ltd

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/81/2/81_CJ-16-1148/_pdf

Reference16 articles.

1. 1. International Diabetes Federation, IDF Atlas (7th edn) 2015. http://www.diabetesatlas.org/ (accessed November 8, 2016).

2. 2. Golden SH, Brown A, Cauley JA, Chin MH, Gary-Webb TL, Kim C, et al. Health disparities in endocrine disorders: Biological, clinical, and nonclinical factors: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2012; 97: E1579–E1639.

3. 3. Tillin T, Hughes AD, Mayet J, Whincup P, Sattar N, Forouhi NG, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited): A prospective population-based study. J Am Coll Cardiol 2013; 61: 1777–1786.

4. 4. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010; 375: 408–418.

5. 5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials;Frontiers in Endocrinology;2024-08-23

2. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association;Diabetes & Metabolism Journal;2024-07-31

3. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version);Journal of Diabetes Investigation;2024-07-11

4. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

5. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes—2nd Edition (English version);Diabetology International;2024-07